Oculis completes Series B funding

Oculis has completed an extension of its Series B funding of 15.5 million Swiss francs, bringing the funding round to a total of 35.5 million Swiss francs, according to a press release.
Led by Tekla Capital Management, the round also included funding from Nan Fung Life Sciences and other current investors. It will support in-licensing and development of Oculis’ products, including a line of topical treatments for major ophthalmic diseases, the release said.
The company plans to develop LME636, a topical anti-TNF alpha antibody it recently in-licensed from Novartis, as (Read more...)

Full Story →